MX2022011409A - Vesiculas extracelulares de diseño para tratar la excitotoxicidad. - Google Patents
Vesiculas extracelulares de diseño para tratar la excitotoxicidad.Info
- Publication number
- MX2022011409A MX2022011409A MX2022011409A MX2022011409A MX2022011409A MX 2022011409 A MX2022011409 A MX 2022011409A MX 2022011409 A MX2022011409 A MX 2022011409A MX 2022011409 A MX2022011409 A MX 2022011409A MX 2022011409 A MX2022011409 A MX 2022011409A
- Authority
- MX
- Mexico
- Prior art keywords
- glutamate
- designer
- excitotoxicity
- cns
- extracellular vesicles
- Prior art date
Links
- 230000003492 excitotoxic effect Effects 0.000 title abstract 3
- 231100000063 excitotoxicity Toxicity 0.000 title abstract 3
- 108010027915 Glutamate Receptors Proteins 0.000 abstract 2
- 102000018899 Glutamate Receptors Human genes 0.000 abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 abstract 2
- 229930195712 glutamate Natural products 0.000 abstract 2
- 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 abstract 2
- 102100037636 Metabotropic glutamate receptor 8 Human genes 0.000 abstract 1
- 238000005034 decoration Methods 0.000 abstract 1
- 108010038448 metabotropic glutamate receptor 8 Proteins 0.000 abstract 1
- 230000007135 neurotoxicity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
En la presente se divulgan vesículas extracelulares (EV) de diseño funcionalizadas con receptores de glutamato (por ejemplo, mGluR4 y mGluR8) que pueden dirigirse selectivamente a regiones lesionadas del SNC que experimentan excitotoxicidad; las EV decoradas con mGluR4 y mGluR8 se anclan preferentemente en áreas lesionadas del SNC con un marcado aumento en el glutamato extracelular asociado con neurotoxicidad y excitotoxicidad profusas; por lo tanto, la decoración con receptor de glutamato puede conducir a un mejor direccionamiento en áreas ricas en glutamato del SNC.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062990783P | 2020-03-17 | 2020-03-17 | |
| PCT/US2021/022674 WO2021188616A1 (en) | 2020-03-17 | 2021-03-17 | Designer extracellular vesicles for treating excitotoxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011409A true MX2022011409A (es) | 2022-12-02 |
Family
ID=77771275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011409A MX2022011409A (es) | 2020-03-17 | 2021-03-17 | Vesiculas extracelulares de diseño para tratar la excitotoxicidad. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230226118A1 (es) |
| EP (1) | EP4121117A4 (es) |
| JP (1) | JP2023518218A (es) |
| KR (1) | KR20220154132A (es) |
| CN (1) | CN115666655A (es) |
| AU (1) | AU2021238317A1 (es) |
| BR (1) | BR112022018395A2 (es) |
| CA (1) | CA3175322A1 (es) |
| IL (1) | IL296508A (es) |
| MX (1) | MX2022011409A (es) |
| WO (1) | WO2021188616A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2662326T5 (es) * | 2013-04-12 | 2021-08-04 | Evox Therapeutics Ltd | Vesículas de suministro terapéutico |
| EA201892587A1 (ru) * | 2016-05-20 | 2019-04-30 | Биохэйвен Фармасьютикал Холдинг Компани Лтд. | Использование глутамат-модулирующих средств вместе с иммунотерапией для лечения рака |
| US20190269739A1 (en) * | 2016-11-03 | 2019-09-05 | Exostem Biotec Ltd. | Mesenchymal stem cells populations, their products, and use thereof |
| US11852635B2 (en) * | 2016-11-16 | 2023-12-26 | Nano Somix, Inc | Quantification of subpopulations of exosomes and diagnosis of neurogenerative disorders |
| CN111133106A (zh) * | 2017-07-12 | 2020-05-08 | 外来体诊断公司 | 用于分离和富集生物流体来源的细胞外囊泡的方法及其使用方法 |
-
2021
- 2021-03-17 KR KR1020227033475A patent/KR20220154132A/ko unknown
- 2021-03-17 AU AU2021238317A patent/AU2021238317A1/en active Pending
- 2021-03-17 IL IL296508A patent/IL296508A/en unknown
- 2021-03-17 WO PCT/US2021/022674 patent/WO2021188616A1/en unknown
- 2021-03-17 US US17/906,279 patent/US20230226118A1/en active Pending
- 2021-03-17 EP EP21770606.8A patent/EP4121117A4/en active Pending
- 2021-03-17 MX MX2022011409A patent/MX2022011409A/es unknown
- 2021-03-17 BR BR112022018395A patent/BR112022018395A2/pt unknown
- 2021-03-17 CN CN202180023391.7A patent/CN115666655A/zh active Pending
- 2021-03-17 JP JP2022555143A patent/JP2023518218A/ja active Pending
- 2021-03-17 CA CA3175322A patent/CA3175322A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021238317A1 (en) | 2022-09-29 |
| IL296508A (en) | 2022-11-01 |
| US20230226118A1 (en) | 2023-07-20 |
| EP4121117A4 (en) | 2024-04-17 |
| CA3175322A1 (en) | 2021-09-23 |
| KR20220154132A (ko) | 2022-11-21 |
| EP4121117A1 (en) | 2023-01-25 |
| JP2023518218A (ja) | 2023-04-28 |
| BR112022018395A2 (pt) | 2023-02-28 |
| WO2021188616A1 (en) | 2021-09-23 |
| CN115666655A (zh) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20200101A (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39 | |
| PH12018500810A1 (en) | Antibody agents specific for human cd19 and uses thereof | |
| TN2009000529A1 (en) | Methods and compositions for treating allergic diseases | |
| MX2017014199A (es) | Composiciones de nanoparticulas para terapia sostenida. | |
| MY188183A (en) | Antibodies to alpha-synuclein and uses thereof | |
| MX2017003247A (es) | Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas. | |
| NZ585108A (en) | Methods of treating urogenital-neurological disorders using modified clostridial toxins | |
| MX2022002489A (es) | Composiciones de neurotoxinas para usarse en el tratamiento contra cefalea. | |
| EA201692568A1 (ru) | Составы с полипептидами-рецепторами и связанные с ними способы | |
| MX2012013031A (es) | Potenciadores alostericos mglur4 de sulfona heterociclica, composiciones y metodos para tratar disfuncion neurologica. | |
| MX354099B (es) | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. | |
| PH12019500624A1 (en) | Swine comprising modified cd163 and associated methods | |
| WO2009082038A3 (en) | Ampa receptor antagonists and zonisamide for epilepsy | |
| MX2019009848A (es) | Proteínas que se unen a her2, nkg2d y cd16. | |
| MY159244A (en) | Method of reducing intraocular pressure in humans | |
| EA201891376A1 (ru) | Бензотиофеновые селективные блокаторы эстрогеновых рецепторов | |
| MX2019002672A (es) | Usos de antagonistas de il-13 para el tratamiento de dermatitis atopica. | |
| TN2018000021A1 (en) | ANTl-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY. | |
| MX2021015992A (es) | Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico. | |
| MX2021015337A (es) | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3. | |
| SG10201805749QA (en) | Substantially animal protein-free recombinant furin and methods for producing same | |
| MX2023009867A (es) | Composiciones de neurotoxina para usarse en el tratamiento del dolor de cabeza. | |
| MX2022011248A (es) | Metodos y composiciones relacionados con nanoportadores sinteticos. | |
| MX2022011409A (es) | Vesiculas extracelulares de diseño para tratar la excitotoxicidad. | |
| MX2019009847A (es) | Proteínas que se unen a cd123, nkg2d y cd16. |